8-K current report · filed Jul 15, 2026

Pediatrix Medical Group, Inc. (MD) 8-K Current Report: July 15, 2026

Item EX-99.1Item 2.02Item 7.01MD overview

Short answer

Pediatrix Medical Group, Inc. (MD) filed an 8-K current report with the SEC on July 15, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Pediatrix issued an update covering recently completed second-quarter fiscal 2026 results.

Pediatrix Medical Group, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Pediatrix issued an update covering recently completed second-quarter fiscal 2026 results
  • Exhibit 99.1 contains the substantive financial results and management commentary for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 payor mix remained stable, with no unfavorable shifts reported by other healthcare companies
  • No material changes in net revenue trends versus recent historical periods, reducing near-term reimbursement risk
  • FY2026 Adjusted EBITDA guidance reaffirmed at $280 million–$300 million
  • Guidance reconciliation implies net income of $152.1 million–$166.7 million
  • Q2 results and detailed financial release scheduled for August 4, 2026 before market open

Other items in this filing:

  • Item 7.01: Regulation FD Disclosure

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Pediatrix Medical Group, Inc. 8-K filings

Get the next MD 8-K as it lands

Follow MD for push alerts, or ask the research agent what this filing means.